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Introduction
Maternal diabetes has toxic effects on the development
of the embryo and significantly increases the risk of
congenital malformations in humans. The incidence of
fetal structural defects caused by maternal pregestational
diabetes is three- to fourfold higher than that caused
by non-diabetic pregnancy [1–7]. The congenital
malformations associated with diabetic pregnancy arise
before the seventh gestational week [5]. Diabetic
embryopathy can affect any developing organ system,
including the central nervous system (anencephaly, spina
bifida, microcephaly, and holoprosencephaly), skeletal
system (caudal regression syndrome, sacral agenesis,
and limb defects), renal system (renal agenesis,
hydronephrosis, and ureteric abnormalities), cardio-
vascular system (transposition of the great vessels,
ventricular septal defects, atrial septal defects,
coarctation of the aorta, cardiomyopathy, and single
umbilical artery), and gastrointestinal system (duo-
denal atresia, anorectal atresia, and small left colon
syndrome) [8,9].
Pregnant women with fetuses with diabetic
embryopathy may have chronic or unrecognized
hyperglycemia and elevated levels of glycerated
hemoglobin. This review emphasizes the necessity to
consider hyperglycemia-induced teratogenesis during
genetic counseling of parents with prenatally detected
SUMMARY
Maternal diabetes has toxic effects on the development of the embryo and significantly increases the risk of
congenital malformations in humans. The incidence of fetal structural defects caused by maternal pregestational
diabetes is three- to fourfold higher than that caused by non-diabetic pregnancy. The congenital malformations
associated with diabetic pregnancy arise before the seventh gestational week. Diabetic embryopathy can affect
any developing organ system, including the central nervous system (CNS) (anencephaly, spina bifida,
microcephaly, and holoprosencephaly), skeletal system (caudal regression syndrome, sacral agenesis, and limb
defects), renal system (renal agenesis, hydronephrosis, and ureteric abnormalities), cardiovascular system
(transposition of the great vessels, ventricular septal defects, atrial septal defects, coarctation of the aorta,
cardiomyopathy, and single umbilical artery), and gastrointestinal system (duodenal atresia, anorectal atresia,
and small left colon syndrome). Pregnant women with fetuses with diabetic embryopathy may have chronic
or unrecognized hyperglycemia and elevated levels of glycerated hemoglobin. This review emphasizes the necessity
to consider hyperglycemia-induced teratogenesis during genetic counseling of parents with prenatally detected
fetal malformations. Successful preconception counseling for women with diabetes mellitus and metabolic
control will reduce birth defects and maternal morbidity. [Taiwanese J Obstet Gynecol 2005;44(1):1–7]
Key Words: congenital malformations, diabetes mellitus, pregnancy
■  REVIEW ARTICLE  ■
C.P. Chen
Taiwanese J Obstet Gynecol • March 2005 • Vol 44 • No 12
fetal malformations. Successful preconception
counseling for women with diabetes mellitus and
metabolic control will reduce birth defects and maternal
morbidity.
Classification of Diabetes Mellitus
A practical classification of type 1, type 2, and gestational
diabetes, and other specific types based on the
etiopathology of hyperglycemia has been adopted by
the American Diabetes Association (Table) [10].
Type 1 diabetes
The cause of type 1 diabetes is an absolute deficiency of
insulin secretion. Type 1 diabetes is divided into two
categories: immune-mediated diabetes and idiopathic
diabetes.
Immune-mediated diabetes, formerly termed insulin-
dependent diabetes mellitus (IDDM) or juvenile-onset
diabetes mellitus, is an autoimmune disorder involving
islet cell autoantibodies, autoantibodies to insulin,
autoantibodies to glutamic acid decarboxylase, and
autoantibodies to the tyrosine phosphatase IA-2 and
IA-2` that cause cellular-mediated autoimmune
destruction of the `-cells of the pancreas. This disorder
results from a complex interaction of genetic and
environmental factors. It develops in individuals with
a strong genetic susceptibility and has human leukocyte
antigen (HLA) associations. Patients are prone to other
autoimmune disorders such as Hashimoto’s thyroiditis,
Grave’s disease, Addison’s disease, vitiligo, and
pernicious anemia. Environmental factors such as viral
infection are necessary to trigger the intense and
progressive autoimmune destruction of the pancreatic
islet cells. Immune-mediated diabetes generally occurs
in lean individuals younger than 40 years old, with the
onset usually at younger than 30 years, and a tendency
to ketoacidosis. The onset is typically abrupt with acute
or subacute appearance of symptoms with marked
Table. Classification of diabetes mellitus by the American Diabetes Association [10]
I. Type 1 diabetes
A. Immune-mediated
B. Idiopathic
II. Type 2 diabetes
III. Other specific types
A. Genetic defects of `-cell function
1. Chromosome 12, HNF-1_ (MODY3)
2. Chromosome 7, glucokinase (MODY2)
3. Chromosome 20, HNF-4_ (MODY1)
4. Mitochondrial DNA
5. Others
B. Genetic defects in insulin action
1. Type A insulin resistance
2. Leprechaunism
3. Rabson-Mendenhall syndrome
4. Lipoatrophic diabetes
5. Others
C. Diseases of the exocrine pancreas
1. Pancreatitis
2. Trauma/pancreatectomy
3. Neoplasia
4. Cystic fibrosis
5. Hemochromatosis
6. Fibrocalculous pancreatopathy
7. Others
IV. Gestational diabetes mellitus
HNF = hepatocyte nuclear factor; MODY = maturity-onset diabetes of the young.
D. Endocrinopathies
1. Acromegaly
2. Cushing’s syndrome
3. Glucagonoma
4. Pheochromocytoma
5. Hyperthyroidism
6. Somatostatinoma
7. Aldosteronoma
8. Others
E. Drug- or chemical-induced
1. Vacor
2. Pentamidine
3. Nicotinic acid
4. Glucocorticoids
5. Thyroid hormone
6. Diazoxide
7. `-adrenergic agonists
8. Thiazides
9. Dilantin
10. _-Interferon
11. Others
F. Infections
1. Congenital rubella
2. Cytomegalovirus
3. Others
G. Uncommon forms of immune-
mediated diabetes
1. “Stiff-man” syndrome
2. Anti-insulin receptor antibodies
3. Others
H. Other genetic syndromes sometimes
associated with diabetes
1. Down syndrome
2. Klinefelter’s syndrome
3. Turner’s syndrome
4. Wolfram’s syndrome
5. Friedreich’s ataxia
6. Huntington’s chorea
7. Laurence-Moon-Biedl syndrome
8. Myotonic dystrophy
9. Porphyria
10. Prader-Willi syndrome
11. Others
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hyperglycemia, weight loss, fatigue, polyuria, polydipsia,
and volume contraction. The plasma insulin level is
low to absent. Immune-mediated diabetes responds
to insulin therapy, which is required for life. The
concordance rate for this form of type 1 diabetes in
monozygotic twins is 20–50%.
While most type 1 diabetes patients have immune-
mediated diabetes, some have idiopathic diabetes.
Idiopathic diabetes is strongly inherited, lacks `-cell
autoimmunity, and is not HLA associated. Patients
have permanent insulinopenia and are prone to
ketoacidosis but have no evidence of autoimmunity.
Type 2 diabetes
Type 2 diabetes, formerly termed non-insulin-dependent
diabetes mellitus (NIDDM) or adult-onset diabetes
mellitus, is a progressive insulin-resistant disorder
without autoimmune or HLA associations. It results
from a combination of pancreatic insufficiency,
peripheral insulin resistance, and augmented hepatic
glucose production. This disorder has a familial
occurrence and is increasingly recognized among
overweight children, obese adults, young adults with
a family history of diabetes, and ethnic groups
with high rates of diabetes. It generally occurs in
individuals older than 40 years and has no tendency to
ketoacidosis. The appearance of symptoms such as
hyperglycemia, hyperlipidemia, and tissue insulin
resistance is usually slow. The plasma insulin level is
variable. Diet control or oral hypoglycemic agents
may be sufficient to control hyperglycemia, although
insulin may be required. The concordance rate for type
2 diabetes in monozygotic twins is 100%. Risk factors
for type 2 diabetes include aging, obesity, sedentary
lifestyle, and lack of physical activity. This disorder
occurs more frequently in women with prior gestational
diabetes mellitus and in individuals with hypertension
and dyslipidemia.
Gestational diabetes
Gestational diabetes is defined as diabetes that begins
or is first diagnosed during pregnancy [11]. Pre-
gestational diabetes mellitus is defined as type 1 or
type 2 diabetes that exists before the pregnancy. The
terminology of gestational diabetes does not distinguish
between unrecognized type 2 diabetes and preclinical
type 2 diabetes unmasked by the hormonal stress
imposed by the pregnancy. Since more than half of
women with gestational diabetes eventually develop
overt diabetes in the following 20 years and type 2
diabetes may be first diagnosed as gestational diabetes,
postpartum follow-up tests (e.g. 6 weeks or more after
delivery) are necessary.
Diagnosis
Diagnostic criteria for diabetes mellitus
The diagnostic criteria for diabetes mellitus proposed
by the American Diabetes Association [10,11] include
symptoms of diabetes plus a casual plasma glucose
concentration of at least 200 mg/dL (11.1 mmol/L)
and a fasting plasma glucose concentration of at least
126 mg/dL (7.0 mmol/L) or a 2-hour post-load glucose
concentration of at least 200 mg/dL (11.1 mmol/L)
during an oral glucose tolerance test (OGTT) using a
glucose load of 75 g anhydrous glucose.
Diagnostic criteria for impaired glucose tolerance and
impaired fasting glucose
Impaired glucose tolerance (IGT) and impaired fasting
glucose (IFG) denote a metabolic stage intermediate
between normoglycemia and diabetes mellitus. The
term IGT refers to a 2-hour post-load glucose con-
centration of at least 140 mg/dL (7.8 mmol/L) and less
than 200 mg/dL (11.1 mmol/L). The term IFG refers
to a fasting plasma glucose concentration of at least
110 mg/dL (6.1 mmol/L) and less than 126 mg/dL
(7.0 mmol/L) [10].
Diagnostic criteria for normoglycemia
Normoglycemia or normal glucose homeostasis is
defined as a fasting plasma glucose concentration of
less than 110 mg/dL (6.1 mmol/L) or a 2-hour post-
load glucose concentration of less than 140 mg/dL
(7.8 mmol/L) [10].
Glycated hemoglobin measurement and diabetes
mellitus
Glycated hemoglobin, also known as glyco-
hemoglobin, glycosylated hemoglobin, HbA1C, or HbA1,
is used to describe minor hemoglobin components
formed slowly and non-enzymatically from glucose and
hemoglobin. The rate of formation of glycated
hemoglobin is directly proportional to the ambient
glucose concentration. Because erythrocytes are freely
permeable to glucose and the average erythrocyte life
span is 120 days, the level of glycated hemoglobin in
blood samples provides the glycemic history of the
previous 120 days.
Glycated hemoglobin measurement, or the HbA1C
test, is useful for monitoring glycemia [12–14] but is not
currently recommended for the diagnosis of diabetes
[10]. Fasting plasma glucose and HbA1C have become
the measurements of choice in monitoring the treatment
of diabetes. Glycated hemoglobin measurement predicts
the risk of developing many of the chronic complications
of diabetes [14]. The American Diabetes Association
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recommends a fasting plasma glucose concentration of
less than 120 mg/dL (6.7 mmol/L) and an HbA1C of less
than 7% as treatment goals [15].
Diagnostic criteria for gestational diabetes
The diagnosis of gestational diabetes is based on the
diagnostic criteria for diabetes mellitus or an OGTT.
Diagnostic criteria for the 100 g OGTT are two or
more venous plasma concentrations exceeding the
glucose threshold values: 95 mg/dL (5.3 mmol/L)
at fasting, 180 mg/dL (10.0 mmol/L) at 1 hour,
155 mg/dL (8.6 mmol/L) at 2 hours, and 140 mg/dL
(7.8 mmol/L) at 3 hours [11].
Congenital Malformations Associated with
Maternal Diabetes
Congenital anomalies of the central nervous system
(CNS), heart, and renal and urinary tracts, lower limb
reduction defects, axial skeleton defects, and caudal
dysgenesis complex are more frequent among the
children of mothers with pregestational diabetes than
among children with non-diabetic mothers [16]. For
instance, the frequency of CNS anomalies is 2.9 times
higher in children of pregestational diabetic mothers
than in children of non-diabetic mothers [16]. Ray et al
observed a higher risk of open neural tube defects and
urinary tract disorders in association with the presence
of pregestational diabetes among women undergoing
second-trimester screening [17]. Gestational diabetes
is associated with a significant risk of holoprosencephaly,
upper/lower spine/rib defects, and renal and urinary
system anomalies [18]. Martínez-Frías et al suggested
that holoprosencephaly is significantly associated with
gestational diabetes while neural tube defects are not
[18].
It has been postulated that hyperglycemia-induced
teratogenesis is caused by several mechanisms, such as
functional deficiencies of arachidonic acid and myo-
inositol [19,20]; inhibition of the cellular uptake of
dehydroascorbic acid [21] and increased non-enzymatic
glycosylation of embryonic proteins [22]; decreased
catalase activity [23] and increased substrate-induced
free-oxygen radical production [24]; and abnormal
levels of trace metals [20].
Caudal regression syndrome
Caudal regression syndrome is characterized by varying
degrees of vertebral anomalies from partial sacral
agenesis to complete absence of the lumbosacral spine.
It is the most characteristic congenital anomaly observed
in the children of diabetic women [16]. Sixteen percent
of caudal regression syndrome cases have occurred in
the offspring of diabetic mothers, and about 1% of the
infants born to diabetic mothers exhibit caudal regression
syndrome, indicating a risk at least 250 times higher
than that of the offspring of non-diabetic mothers [25–
27].
Recently, Chan et al found a significantly increased
incidence of retinoic acid-induced caudal regression in
embryos of diabetic mice compared with embryos of
non-diabetic mice and presented evidence that the
increased susceptibility to caudal regression is mediated
via enhanced down-regulation by retinoic acid of
Wnt-3a expression in the embryo exposed to a diabetic
milieu [27]. Martínez-Frías suggested that the highest
risk of congenital defects in the offspring of diabetic
pregnant women is caudal dysgenesis [16]. Prenatal
sonographic examination of diabetic mothers should
include a thorough examination of the fetal spine.
Holoprosencephaly
About 1–2% of newborn infants from diabetic mothers
develop holoprosencephaly, indicating a 200-fold
risk of holoprosencephaly compared with controls
[28,29]. Martínez-Frías et al found that pregnant
women with gestational diabetes have a significant
risk of holoprosencephaly [18]. The pathogenesis in
maternal diabetes is due to hyperglycemia, hypo-
glycemia, hypoxia, maternal vasculopathy, ketones,
amino acid abnormalities, glycosylation of proteins,
hormonal imbalances, and somatomedian inhibitors
[29–33].
Neural tube defects
Mills et al found a twofold ratio of incidence of spina
bifida, hydrocephalus, and other CNS defects and a
threefold ratio of incidence of anencephaly in infants of
diabetic mothers compared with those of controls [5].
Ray et al found an increased risk of having a fetus with
an open neural tube defect among pregestational
diabetic women undergoing second-trimester maternal
serum screening [17]. Recently, impaired expression of
developmental control genes has been shown to be a
cause of defective morphogenesis in the mouse model
of diabetic embryopathy and genotoxicity. For instance,
impaired expression of Pax-3, a gene that regulates
neural tube closure, is sufficient to prevent normal
formation of the neural tube [34]. Phelan et al noted a
significant reduction in the expression of Pax-3 in
embryos of diabetic mice before the manifestation
of morphologic defects [35]. Fine et al showed that
hyperglycemia inhibits Pax-3 gene expression and
increases neuroepithelial apoptosis in the embryo,
leading to neural tube defects [36]. Chang et al dem-
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onstrated that oxidative stress in the embryo caused by
maternal hyperglycemia inhibits expression of Pax-3
and contributes to the occurrence of neural tube defects
in diabetic pregnancy [37]. Pani et al provided evidence
for polymorphic susceptibility to the molecular causes
of neural tube defects during diabetic embryopathy
[38]. They also found that Pax-3 regulates neural tube
closure by inhibiting p53-dependent apoptosis [39].
Loeken concluded that maternal diabetes causes
birth defects such as neural tube defects by disturbing
expression of genes that control essential developmen-
tal processes, and that oxidative stress is involved
[40]. She further hypothesized that antioxidants, either
vitamin E, vitamin C, a combination of antioxidants
and lipids, or N-acetyl-cysteine, might have a positive
impact on the outcome of human pregnancy [40].
Congenital heart defects
Congenital heart defects are the most frequent
malformations but are not the most characteristic
abnormalities among children of diabetic mothers with
or without insulin treatment. Martínez-Frías found that
congenital heart anomalies made up 21% of all anomalies
among children of diabetic mothers; however, the
frequency of congenital heart defects was only 2.8 times
higher than that in children of non-diabetic mothers
[16]. Schaefer-Graf et al found that the most commonly
affected organs in congenital anomalies caused by
pregnancies complicated by type 2 and gestational
diabetes were the heart (37.6%), musculoskeletal system
(14.7%), and CNS (9.8%) [41].
Other anomalies
Maternal diabetes is related to heterotaxia-asymmetry,
particularly transposition of great vessels and trans-
position of viscera, but situs inversus totalis does not
appear to be related to maternal diabetes [42]. Martínez-
Frías found heterotaxia-asymmetry in 6.15% of infants
of mothers with diabetes mellitus, in 1.92% of infants of
mothers with gestational diabetes, and in 0.99% of
infants of non-diabetic mothers; the differences were
statistically significant [42]. Vaux et al found a striking
similarity between the structural defects previously not-
ed in both animals and humans with abnormalities in
sonic hedgehog signaling and the defects seen in in-
fants of diabetic mothers, and suggest that maternal
diabetes may affect sonic hedgehog expression in
susceptible tissues during critical stages of development
[43]. The reported congenital malformations common
to sonic hedgehog abnormalities and infants of diabetic
mothers include aphallia, hypospadias, megalourethra,
urogenital malformation sequence, hydronephrosis,
renal agenesis, horseshoe kidneys, vertebral seg-
mentation defects, polydactyly, sacral defects, limb
deficiency, esophageal atresia, tracheoesophageal
atresia, anal stenosis/imperforate anus, urorectal sep-
tum malformation sequence, intestinal malrotation/
atresia, holoprosencephaly, and cardiac laterality de-
fects [43].
Preconception Maternal Glycemic Control
and the Prevention of  Diabetic Embryopathy
Mills et al found that malformations in infants of diabetic
mothers occur before the seventh gestational week and
suggest that any therapeutic intervention aimed at
decreasing congenital malformations must be instituted
during the critical early period [5]. In fact, patient
education and initiating intensive management for
glycemic control in diabetic women before conception
significantly decrease the risk of congenital malfor-
mations [44–47]. For instance, Fuhrmann et al found a
0.8% incidence of congenital malformations in infants
born to diabetic mothers with intensive treatment
before conception, while there was a 7.5% incidence
of congenital malformations in infants born to diabetic
mothers with strict metabolic control after 8 weeks’
gestation [44]. Steel et al reported lower glycated
hemoglobin levels, a higher incidence of hypoglycemia,
and fewer infants with congenital abnormalities (1.4%
vs 10.4%) among insulin-dependent diabetic women
with specific preconception maternal glycemic control
compared with insulin-dependent diabetic mothers
without pregestational care [45]. Kitzmiller et al
described a 1.2% incidence of major anomalies among
infants in the preconception care group of diabetic
mothers compared with 10.9% in the postconception
group [46]. Willhoite et al documented a 1.6% incidence
of major congenital anomalies among infants born to
pregestational diabetic women receiving preconception
counseling compared with 6.4% in the group without
preconception counseling [47]. In view of the importance
of preventing diabetic embryopathy, preconception
recognition of the maternal status of glycemic control
and early intensive diabetes management are the most
beneficial and cost-effective methods for promoting
maternal and fetal health in the perinatal management
of maternal diabetes.
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